



OPPI



Organisation of Pharmaceutical Producers of India

APRIL 2025

Date	Headline and Source	Link	Summary
1 st April	Experimental drug lapidarian cuts heart disease risk factor by 94% The Times of India, April 01, 2025	Experimental drug lapidarian cuts heart disease risk factor by 94%	A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by 94%. Lepodisiran, an experimental drug developed by Eli Lilly, has shown promising results in reducing levels of lipoprotein(a), or Lp(a), a genetically inherited particle linked to an increased risk of heart attacks and strokes.
2 nd April	AstraZeneca backs AI to accelerate lung cancer screening, shares evidence on impact in resource limited settings ET Health World, April 02, 2025	AstraZeneca backs AI to accelerate lung cancer screening, shares evidence on impact in resource limited settings	Innovation in healthcare is crucial for transforming patient outcomes. By leveraging AI technology for lung cancer detection, especially in resource limited settings, we aim to enhance early diagnosis and ultimately improve survival rates, said Sanjeev Panchal, Country President and Managing Director, AstraZeneca India Pharma.
3 rd April	CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ianalumab study Medical Dialogues, April 03, 2025	CDSCO Panel Approves Novartis Protocol Amendment Proposal for Ianalumab study	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by Novartis for the clinical trial titled A phase 3, randomized, double-blind, study to assess efficacy and safety of Ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA).
3 rd April	Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform The Financial Express, April 03, 2025	Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform	Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly's weight-loss drug. This comes after plans to widen its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.
3 rd April	Novo Nordisk's oral diabetes drug Rybelsus shows 14% drop in heart disease risk ET Edge Insights, April 03, 2025	Novo Nordisk's oral diabetes drug Rybelsus shows 14% drop in heart disease risk	In a breakthrough clinical trial, Novo Nordisk's oral diabetes drug, Rybelsus, has demonstrated significant cardiovascular benefits, reinforcing its potential as a game-changer for patients with both diabetes and heart disease. The late-stage study revealed that Rybelsus reduces the risk of cardiovascular death, heart attack, and stroke by 14% over four years compared to a placebo.



OPPI



Organisation of Pharmaceutical Producers of India

6 th April	AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib) Business Standard, April 06, 2025	AstraZeneca Pharma gets CDSCO nod to import and distribute TAGRISSO (Osimertinib)	AstraZeneca Pharma India announced that it has received approval from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, to import and distribute Osimertinib Tablets (TAGRISSO).
8 th April	AstraZeneca Pharma India gets CDSCO nod to import, distribute lung cancer drug Osimertinib Medical Dialogues, April 08, 2025	AstraZeneca Pharma India gets CDSCO nod to import, distribute lung cancer drug Osimertinib	AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication.
9 th April	Bayer Pharmaceutical Gets CDSCO Panel Nod To Import, Market Recombinant Factor VIII Medical Dialogues, April 09, 2025	Bayer Pharmaceutical Gets CDSCO Panel Nod To Import, Market Recombinant Factor VIII	Bayer Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to import and market the product Antihemophilic Factor (Recombinant Factor VIII) PEGylated auctl 500 IU/1000 IU/2000 IU/3000 IU (Damoctocog Alfa Pegol) with the condition to conduct a Phase-IV study in India
10 th April	Popular diabetes drug, Mounjaro, launched in India The Times of India, April 10, 2025	Popular diabetes drug, Mounjaro, launched in India	The common side effects of the drug are nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain, as per Eli Lilly. Warning: Eli Lilly advises against the use of Mounjaro if one has symptoms like a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath.
10 th April	BT Exclusive: India launch of Wegovy brought forward to 2025, says Novo Nordisk India chief Business Today, April 10, 2025	BT Exclusive: India launch of Wegovy brought forward to 2025, says Novo Nordisk India chief	As India grapples with a mounting obesity crisis with over 250 million individuals affected and health costs projected to reach 1.57 per cent of GDP by 2030 Danish pharmaceutical company Novo Nordisk is accelerating plans to bring its blockbuster weight-loss drug, Wegovy, to the Indian market.
14 th April	AstraZeneca Gets CDSCO Panel Nod To study Tezepelumab Medical Dialogues, April 14, 2025	AstraZeneca Gets CDSCO Panel Nod To study Tezepelumab	Pharmaceutical major AstraZeneca Pharma India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to conduct the Phase III clinical trial of Tezepelumab.
22 nd April	PADCEV (enfortumab vedotin) Now Available in India for Locally Advanced or Metastatic Urothelial Cancer	PADCEV (enfortumab vedotin) Now Available in India for Locally Advanced or Metastatic Urothelial Cancer	Astellas Pharma India Pvt Ltd. today announced that PADCEV™ (enfortumab vedotin) is now available for prescription in India as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer (LA/mUC) who



OPPI



Organisation of Pharmaceutical Producers of India

	ET Health World, April 22, 2025		have previously received a platinum-containing chemotherapy and a programmed death receptor-1 or programmed death-ligand 1 inhibitor1.
22 nd April	AbbVie enters India oncology market with much-awaited launch of leukemia drug Venetoclax Money Control, April 22, 2025	AbbVie enters India oncology market with much-awaited launch of leukemia drug Venetoclax	US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology market as it seeks to address the challenges of treating Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL). The move comes as India grapples with a rising burden of AML, particularly among its aging population.
24 th April	Ease drug innovation Hindu BuisnessLine, April 24, 2025	Ease drug innovation	China's pharmaceutical industry is witnessing a seismic shift as it transitions from prioritising generic drug production to developing innovative drugs, including small molecules, biologics, and traditional Chinese medicines. In comparison, India has been unable to harness its full potential to help it be a truly innovative nation. For that, our defensive position on IP must change.
25 th April	Ganga Hospital becomes the global training hub for orthopaedic surgeons across Asia Pacific The Covai Mail, April 25, 2025	Ganga Hospital becomes the global training hub for orthopaedic surgeons across Asia Pacific	A Memorandum of Understanding (MoU) was signed between the Ganga Hospital, Coimbatore, and Johnson & Johnson Medtech at the hospital on 23rd April 2025. The MoU was signed in the presence of Dr. Rajasekaran, Chairman, Department of Orthopaedics at the hospital; Kanakavalli Shanmuganathan.
28 th April	Patents Rules: Effective Intellectual Property Regime Paramount for Fostering Innovation and International Trade ET Pharma, April 28, 2025	Patents Rules: Effective Intellectual Property Regime Paramount for Fostering Innovation and International Trade	OPPI believes that India has the potential to be a global leader in R&D-based industries. Indian scientists have demonstrated their critical research talent in the biotech and pharmaceutical spheres, and with the right commercial incentives, can help bring R&D to India.
28 th April	Dengue vaccine Qdenga to launch in India next year The Times of India, April 28, 2025	Dengue vaccine Qdenga to launch in India next year	Japanese major Takeda plans to launch its dengue vaccine, Qdenga, in India next year, partnering with Hyderabad-based Biological E (Bio E) to align with the Make-in-India initiative Having recognised dengue as a global health challenge, the over \$23 bn company will adopt a tiered pricing model for its first global vaccine to maximise access, Derek Wallace, president, global vaccine business unit, Takeda, told TOI in an exclusive interview

29 th April	Dr Reddy's Laboratories, Sanofi Healthcare partner for respiratory drug Business Standard, April 29, 2025	Dr Reddy's Laboratories, Sanofi Healthcare partner for respiratory drug	Hyderabad-based pharma company Dr Reddy's Laboratories has expanded its strategic partnership with Sanofi Healthcare India Private Limited (SHIPL) to introduce a novel drug, Beyfortus (nirsevimab), in the country. Used for treating respiratory syncytial virus (RSV), the drug is expected to launch in the second quarter of FY26
------------------------	---	---	---
